nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CHRM3—nephrolithiasis	0.84	1	CbGaD
Darifenacin—Airway obstruction NOS—Hydrochlorothiazide—nephrolithiasis	0.0138	0.184	CcSEcCtD
Darifenacin—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.00999	0.133	CcSEcCtD
Darifenacin—CHRM3—ureter—nephrolithiasis	0.00999	0.595	CbGeAlD
Darifenacin—CHRM4—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00781	0.127	CbGpPWpGaD
Darifenacin—CHRM5—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00748	0.121	CbGpPWpGaD
Darifenacin—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00526	0.0853	CbGpPWpGaD
Darifenacin—CHRM2—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.0052	0.0842	CbGpPWpGaD
Darifenacin—Injury—Hydrochlorothiazide—nephrolithiasis	0.00179	0.0238	CcSEcCtD
Darifenacin—CYP3A4—urine—nephrolithiasis	0.00178	0.106	CbGeAlD
Darifenacin—CYP2D6—urine—nephrolithiasis	0.00176	0.105	CbGeAlD
Darifenacin—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00174	0.0231	CcSEcCtD
Darifenacin—CHRM4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00173	0.028	CbGpPWpGaD
Darifenacin—CHRM5—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00165	0.0268	CbGpPWpGaD
Darifenacin—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00159	0.0211	CcSEcCtD
Darifenacin—Clidinium—CHRM3—nephrolithiasis	0.00159	0.231	CrCbGaD
Darifenacin—Trospium—CHRM3—nephrolithiasis	0.00153	0.223	CrCbGaD
Darifenacin—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00151	0.0201	CcSEcCtD
Darifenacin—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00149	0.0198	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00148	0.0197	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00145	0.0193	CcSEcCtD
Darifenacin—CHRM4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00145	0.0235	CbGpPWpGaD
Darifenacin—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00142	0.0189	CcSEcCtD
Darifenacin—CHRM5—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00139	0.0225	CbGpPWpGaD
Darifenacin—Isopropamide—CHRM3—nephrolithiasis	0.00135	0.197	CrCbGaD
Darifenacin—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00131	0.0174	CcSEcCtD
Darifenacin—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0013	0.0172	CcSEcCtD
Darifenacin—Mepenzolate—CHRM3—nephrolithiasis	0.00127	0.186	CrCbGaD
Darifenacin—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0164	CcSEcCtD
Darifenacin—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00122	0.0162	CcSEcCtD
Darifenacin—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00119	0.0158	CcSEcCtD
Darifenacin—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00116	0.0189	CbGpPWpGaD
Darifenacin—CHRM2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00115	0.0186	CbGpPWpGaD
Darifenacin—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00114	0.0152	CcSEcCtD
Darifenacin—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00113	0.015	CcSEcCtD
Darifenacin—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00112	0.0149	CcSEcCtD
Darifenacin—Diphenidol—CHRM3—nephrolithiasis	0.00112	0.163	CrCbGaD
Darifenacin—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0011	0.0146	CcSEcCtD
Darifenacin—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0143	CcSEcCtD
Darifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00106	0.0171	CbGpPWpGaD
Darifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00101	0.0164	CbGpPWpGaD
Darifenacin—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000978	0.0159	CbGpPWpGaD
Darifenacin—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000977	0.013	CcSEcCtD
Darifenacin—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000971	0.0129	CcSEcCtD
Darifenacin—CHRM2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000965	0.0156	CbGpPWpGaD
Darifenacin—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000959	0.0128	CcSEcCtD
Darifenacin—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000935	0.0124	CcSEcCtD
Darifenacin—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000906	0.0121	CcSEcCtD
Darifenacin—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000889	0.0118	CcSEcCtD
Darifenacin—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000876	0.0117	CcSEcCtD
Darifenacin—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000872	0.0116	CcSEcCtD
Darifenacin—Cough—Hydrochlorothiazide—nephrolithiasis	0.000865	0.0115	CcSEcCtD
Darifenacin—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000844	0.0112	CcSEcCtD
Darifenacin—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000826	0.011	CcSEcCtD
Darifenacin—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000816	0.0109	CcSEcCtD
Darifenacin—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000809	0.0108	CcSEcCtD
Darifenacin—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000809	0.0108	CcSEcCtD
Darifenacin—Shock—Hydrochlorothiazide—nephrolithiasis	0.000796	0.0106	CcSEcCtD
Darifenacin—CHRM3—renal system—nephrolithiasis	0.000794	0.0473	CbGeAlD
Darifenacin—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00079	0.0105	CcSEcCtD
Darifenacin—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000783	0.0104	CcSEcCtD
Darifenacin—CHRM3—kidney—nephrolithiasis	0.000768	0.0457	CbGeAlD
Darifenacin—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000737	0.00981	CcSEcCtD
Darifenacin—CHRM4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000735	0.0119	CbGpPWpGaD
Darifenacin—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000732	0.00974	CcSEcCtD
Darifenacin—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000722	0.0096	CcSEcCtD
Darifenacin—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00072	0.00957	CcSEcCtD
Darifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000713	0.0116	CbGpPWpGaD
Darifenacin—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000713	0.00948	CcSEcCtD
Darifenacin—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000711	0.0115	CbGpPWpGaD
Darifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000704	0.0114	CbGpPWpGaD
Darifenacin—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000692	0.00921	CcSEcCtD
Darifenacin—Pain—Hydrochlorothiazide—nephrolithiasis	0.000692	0.00921	CcSEcCtD
Darifenacin—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000667	0.00887	CcSEcCtD
Darifenacin—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000662	0.0088	CcSEcCtD
Darifenacin—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00064	0.00851	CcSEcCtD
Darifenacin—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000596	0.00793	CcSEcCtD
Darifenacin—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000581	0.00773	CcSEcCtD
Darifenacin—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000573	0.00762	CcSEcCtD
Darifenacin—CHRM5—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00057	0.00925	CbGpPWpGaD
Darifenacin—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000554	0.00737	CcSEcCtD
Darifenacin—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000535	0.00712	CcSEcCtD
Darifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000516	0.00837	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000516	0.00837	CbGpPWpGaD
Darifenacin—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000515	0.00685	CcSEcCtD
Darifenacin—Rash—Hydrochlorothiazide—nephrolithiasis	0.00051	0.00679	CcSEcCtD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00051	0.00827	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.00051	0.00827	CbGpPWpGaD
Darifenacin—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00051	0.00678	CcSEcCtD
Darifenacin—Headache—Hydrochlorothiazide—nephrolithiasis	0.000507	0.00675	CcSEcCtD
Darifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000495	0.00802	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000495	0.00802	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000489	0.00793	CbGpPWpGaD
Darifenacin—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000481	0.0064	CcSEcCtD
Darifenacin—CYP3A4—renal system—nephrolithiasis	0.000437	0.026	CbGeAlD
Darifenacin—CYP2D6—renal system—nephrolithiasis	0.00043	0.0256	CbGeAlD
Darifenacin—CYP3A4—kidney—nephrolithiasis	0.000422	0.0251	CbGeAlD
Darifenacin—CYP2D6—kidney—nephrolithiasis	0.000415	0.0247	CbGeAlD
Darifenacin—CHRM5—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000412	0.00669	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000402	0.00651	CbGpPWpGaD
Darifenacin—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0004	0.00649	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000369	0.00598	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000359	0.00582	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000358	0.00581	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000348	0.00565	CbGpPWpGaD
Darifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000348	0.00565	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000344	0.00557	CbGpPWpGaD
Darifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000344	0.00557	CbGpPWpGaD
Darifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000333	0.0054	CbGpPWpGaD
Darifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000319	0.00517	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00029	0.00471	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000287	0.00466	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000285	0.00462	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000273	0.00443	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00026	0.00421	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000251	0.00407	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—RGS14—nephrolithiasis	0.000241	0.0039	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—RGS14—nephrolithiasis	0.000228	0.0037	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000224	0.00364	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000222	0.00359	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—RGS14—nephrolithiasis	0.000219	0.00354	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000217	0.00352	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000208	0.00337	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—PTH—nephrolithiasis	0.000199	0.00322	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000192	0.00312	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—PTH—nephrolithiasis	0.00019	0.00308	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00019	0.00308	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000188	0.00304	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—DGKH—nephrolithiasis	0.00017	0.00275	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000169	0.00275	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000169	0.00274	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000167	0.00271	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000163	0.00264	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ADCY10—nephrolithiasis	0.000159	0.00257	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—DGKH—nephrolithiasis	0.000154	0.0025	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000154	0.0025	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000153	0.00249	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000152	0.00246	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ADCY10—nephrolithiasis	0.000152	0.00246	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—DGKH—nephrolithiasis	0.000148	0.00239	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000146	0.00237	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000145	0.00234	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RGS14—nephrolithiasis	0.000135	0.00219	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000134	0.00217	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	0.000134	0.00216	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	0.000132	0.00214	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RGS14—nephrolithiasis	0.000129	0.00209	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000123	0.00199	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000118	0.00191	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000114	0.00186	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	0.000114	0.00185	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000113	0.00183	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—PTH—nephrolithiasis	0.000112	0.00182	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CHRM3—nephrolithiasis	0.000111	0.00181	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GRHPR—nephrolithiasis	0.000108	0.00176	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—PTH—nephrolithiasis	0.000108	0.00174	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000107	0.00173	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CHRM3—nephrolithiasis	0.000107	0.00173	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	0.000107	0.00173	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	0.000106	0.00171	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.000104	0.00169	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	0.000104	0.00168	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	0.000103	0.00166	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—PTH—nephrolithiasis	0.000102	0.00165	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—PTH—nephrolithiasis	9.76e-05	0.00158	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AGXT—nephrolithiasis	9.66e-05	0.00157	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—DGKH—nephrolithiasis	9.11e-05	0.00148	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ATP6V0A4—nephrolithiasis	9.11e-05	0.00148	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	9.09e-05	0.00147	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	9.06e-05	0.00147	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	8.97e-05	0.00145	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.72e-05	0.00141	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—DGKH—nephrolithiasis	8.72e-05	0.00141	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	8.28e-05	0.00134	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—APRT—nephrolithiasis	8.21e-05	0.00133	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—SLC26A1—nephrolithiasis	8.21e-05	0.00133	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	8.17e-05	0.00132	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	7.57e-05	0.00123	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	7.55e-05	0.00122	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	7.52e-05	0.00122	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	7.47e-05	0.00121	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	7.42e-05	0.0012	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	6.87e-05	0.00111	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	6.85e-05	0.00111	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	6.79e-05	0.0011	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CHRM3—nephrolithiasis	6.58e-05	0.00107	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GRHPR—nephrolithiasis	6.48e-05	0.00105	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CHRM3—nephrolithiasis	6.31e-05	0.00102	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	6.14e-05	0.000996	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.14e-05	0.000996	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	6.12e-05	0.000992	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.12e-05	0.000992	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.06e-05	0.000983	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	6.06e-05	0.000983	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PTH—nephrolithiasis	6.02e-05	0.000976	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AQP1—nephrolithiasis	5.85e-05	0.000949	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AGXT—nephrolithiasis	5.78e-05	0.000936	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PTH—nephrolithiasis	5.77e-05	0.000935	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APRT—nephrolithiasis	4.91e-05	0.000796	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	4.91e-05	0.000796	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	4.44e-05	0.00072	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	4.38e-05	0.000711	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GRHPR—nephrolithiasis	4.24e-05	0.000687	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PTH—nephrolithiasis	4.06e-05	0.000658	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PTH—nephrolithiasis	4.05e-05	0.000656	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PTH—nephrolithiasis	4.01e-05	0.00065	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AGXT—nephrolithiasis	3.78e-05	0.000612	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AQP1—nephrolithiasis	3.5e-05	0.000567	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APRT—nephrolithiasis	3.21e-05	0.000521	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	3.21e-05	0.000521	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CHRM3—nephrolithiasis	3.16e-05	0.000513	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SPP1—nephrolithiasis	3.02e-05	0.00049	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SPP1—nephrolithiasis	2.9e-05	0.000469	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AQP1—nephrolithiasis	2.29e-05	0.000371	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CHRM3—nephrolithiasis	2.07e-05	0.000335	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	2.04e-05	0.000331	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	2.03e-05	0.000329	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	2.01e-05	0.000326	CbGpPWpGaD
